NCCN Pharmacy Updates: New Agents for Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of novel treatments for soft tissue sarcomas and gastrointestinal stromal tumors.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.
Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (12/9/2020)

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

New NCCN Guidelines for Pediatric Cancers: Multidisciplinary Management of Wilms Tumor (Nephroblastoma)
The NCCN Guidelines for Wilms tumor (nephroblastoma) are new guidelines that will address management of favorable histology Wilms tumor in children. Treatment needs to be carefully selected to maximize cure and minimize long-term toxicities, such as renal failure, cardiac toxicity, and hypertension, because these children with favorable histology Wilms tumor generally have long-term survival if they receive appropriate management.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Ovarian Cancer
More than ever before, gynecologic surgeons, oncologists, and pathologists need to work together to assess treatment options for each patient.
Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (12/3/2020)

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (12/2/2020)

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

New NCCN Guidelines for Pediatric Cancers: Management of Pediatric Aggressive Mature B-Cell Lymphoma
Clinicians who treat pediatric BL and DLBCL need to be informed about the recommendations in the new NCCN Guidelines for Pediatric Aggressive Mature B-Cell Lymphomas so that they can appropriately stratify patients into risk groups, plan initial therapy, and manage common supportive care issues. They also need information on recommended surveillance protocols and treatment of relapsed/refractory disease.
New NCCN Guidelines for Pediatric Cancers: Advancements in the Management of Pediatric Acute Lymphoblastic Leukemia
The NCCN Guidelines for pediatric ALL will help inform clinicians about treatment approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.
Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress for Community Practices (11/10/2020)

Click the Take Course button to access the evaluation.

 

The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.

Pages

Subscribe to RSS - Live Webinar